Copper-Based Metal-Organic Framework Enables ROS Amplification and Drug Potency Activation

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Reactive oxygen species (ROS)-based cancer therapy faces challenges including tumor hypoxia, low endogenous hydrogen peroxide (H2O2) levels, and high glutathione (GSH) concentrations.
• These factors limit the efficacy of ROS-induced cancer treatments, necessitating innovative therapeutic strategies.

Purpose of the Study:

• To develop a hybrid nanomedicine (CaO2@Cu/ZIF-8-ICG@LA, CCZIL) for synergistic cancer therapy.
• To address the limitations of ROS-induced therapy by enhancing ROS generation and integrating multiple therapeutic modalities.

Main Methods:

• Fabrication of a novel hybrid nanomedicine (CCZIL) using a copper-based metal-organic framework (Cu/ZIF-8).
• CCZIL incorporates functionalities for H2O2/O2 self-supplementation, GSH depletion, and photothermal therapy.
• Disulfiram (DSF) chemotherapy (CT) was activated via chelation with Cu2+ within the nanomedicine.

Main Results:

• The developed CCZIL nanomedicine effectively addresses tumor hypoxia and enhances ROS generation through multiple mechanisms.
• The integrated approach of H2O2/O2 self-supplementation, GSH depletion, and photothermal properties significantly amplifies ROS production.
• Chelation of Cu2+ with DSF activated chemotherapy, leading to synergistic therapeutic effects.

Conclusions:

• The CCZIL nanomedicine presents a promising strategy for overcoming the limitations of current ROS-involved cancer therapies.
• This novel approach demonstrates significant potential for synergistic antitumor effects through combined ROS amplification and chemotherapy.